Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DANTROLENE SODIUM vs CHLORZOXAZONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dantrolene sodium dissociates the excitation-contraction coupling in skeletal muscle by inhibiting calcium release from the sarcoplasmic reticulum via ryanodine receptor blockade.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Malignant hyperthermia (treatment and prophylaxis),Upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy) - spasticity,Neuroleptic malignant syndrome (off-label)
Adjunct for relief of acute painful musculoskeletal conditions associated with muscle spasm
25 mg orally once daily for 7 days; then 25 mg three times daily for 7 days; then 50 mg three times daily for 7 days; then 100 mg three times daily. Maximum daily dose: 400 mg. For malignant hyperthermia: 1 mg/kg intravenously, may repeat up to cumulative dose of 10 mg/kg.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
Terminal elimination half-life is approximately 8-10 hours in adults; may be prolonged to 12-15 hours in elderly or patients with hepatic impairment. Steady-state achieved in 3-4 days.
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Hepatic metabolism via oxidative and reductive pathways; minor renal excretion.
Hepatic, primarily via CYP2E1, also CYP1A2 and CYP3A4
Primarily hepatic metabolism; approximately 25% excreted in urine as metabolites, 45-50% in feces via bile; less than 1% unchanged in urine.
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
Approximately 90-95% bound to plasma proteins, primarily albumin.
Approximately 90–95% bound, primarily to albumin.
Apparent Vd is 0.5-1.0 L/kg, indicating distribution into total body water and some tissue binding.
0.46–0.64 L/kg; indicates distribution into total body water.
Oral: 70% (range 20-90% due to first-pass metabolism). Not applicable for IV.
Oral: nearly complete; rapidly absorbed with extensive first-pass metabolism; systemic bioavailability approximately 30–50% due to first-pass effect.
No specific adjustment required for chronic use; caution in renal impairment as dantrolene is hepatically metabolized and renally excreted. For malignant hyperthermia, use standard dosing.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of active metabolite.
Contraindicated in active hepatic disease (Child-Pugh class C). For Child-Pugh class A or B, reduce dose by 50% and monitor liver function; do not exceed 100 mg/day.
Contraindicated in hepatic impairment; avoid use in Child-Pugh class B or C due to risk of hepatotoxicity.
For spasticity in children ≥5 years: initial 0.5 mg/kg orally once daily for 7 days, then 0.5 mg/kg three times daily for 7 days, then increase by 0.5 mg/kg increments every 7 days up to maximum 3 mg/kg/dose three times daily or 100 mg four times daily, whichever is less. For malignant hyperthermia: 1 mg/kg intravenously, may repeat.
Not established; safety and efficacy not studied in pediatric patients.
Initiate at 25 mg orally once daily, increase slowly with monitoring for hepatic and CNS effects. Higher risk of hepatotoxicity and muscle weakness. For malignant hyperthermia, use standard dosing.
Initiate at lower end of dosing range (250 mg 3-4 times daily); monitor for CNS effects (dizziness, drowsiness) and liver function.
Hepatotoxicity: Active liver disease or hepatic impairment (e.g., hepatitis, cirrhosis) is a contraindication. Risk is dose-dependent; discontinue if no benefit within 45 days.
None
Hepatotoxicity: monitor liver function tests (LFTs) at baseline and periodically; discontinue if LFTs elevated or symptoms of hepatitis.,Muscle weakness: may impair ability to walk or perform tasks; caution in patients with compromised pulmonary function.,Carcinogenesis: increased incidence of benign and malignant tumors in animal studies; clinical significance unknown.,Photosensitivity: avoid sun exposure; use sunscreen.
May cause drowsiness, dizziness, or impaired coordination. Caution in patients with hepatic impairment. Discontinue if hypersensitivity reactions occur. Avoid concurrent use with alcohol or other CNS depressants.
Active hepatic disease (e.g., hepatitis, cirrhosis),Known hypersensitivity to dantrolene,Symptomatic muscle weakness where spasticity is needed to maintain function
Hypersensitivity to chlorzoxazone or any component of the formulation; impaired hepatic function
Avoid excessive alcohol consumption due to risk of hepatotoxicity. No specific food restrictions; however, maintain adequate hydration to prevent constipation, a common side effect.
No significant food interactions. Take with or without food. Grapefruit juice may increase drug levels; avoid large quantities.
Dantrolene sodium is not associated with major congenital malformations; however, data are limited. In animal studies, doses above human therapeutic range caused fetal toxicity (reduced fetal weight, increased resorptions). Use during pregnancy only if clearly needed, weighing benefits against potential risks.
Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if clearly needed and after weighing risks vs. benefits. Avoid during first trimester unless necessary.
Limited data; dantrolene is excreted into breast milk in small amounts. Milk-to-plasma ratio is not established. Monitor infant for adverse effects (muscle weakness, sedation). Consider alternative therapy if available.
Not recommended during breastfeeding due to potential for sedation in the infant. No M/P ratio data available.
No specific dosing adjustments are required during pregnancy; however, pharmacokinetic changes (increased volume of distribution, altered protein binding) may necessitate dose adjustments based on clinical response and tolerability. Use lowest effective dose.
No dosage adjustment specific to pregnancy is required based on pharmacokinetic data; however, clinical response should be monitored.
Dantrolene sodium is a direct-acting skeletal muscle relaxant that inhibits calcium release from the sarcoplasmic reticulum. It is the drug of choice for malignant hyperthermia crisis, requiring rapid IV administration at 2.5 mg/kg. For chronic spasticity, start with 25 mg orally daily, titrate slowly to avoid hepatotoxicity; monitor LFTs at baseline and monthly for 3 months, then periodically. Avoid in patients with active liver disease. Dantrolene may cause muscle weakness, including respiratory muscles; caution in patients with compromised pulmonary function.
Chlorzoxazone is a centrally acting muscle relaxant used for acute musculoskeletal pain. Onset of action is within 1 hour; peak effect at 1-2 hours. Monitor for hepatotoxicity, especially with prolonged use or high doses. Can cause drowsiness and impair motor skills; avoid concurrent use with alcohol or other CNS depressants. Tablets may be crushed for patients with swallowing difficulties.
Take dantrolene exactly as prescribed; do not increase dose without consulting your doctor.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, abdominal pain, or unexplained fatigue.,Avoid driving or operating heavy machinery until you know how dantrolene affects you; it may cause dizziness or drowsiness.,Do not abruptly stop taking dantrolene; tapering is needed to prevent rebound spasticity.,Inform all healthcare providers you are taking dantrolene, especially before surgery.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report signs of liver problems: dark urine, yellowing of eyes/skin, persistent nausea, abdominal pain.,Do not suddenly stop taking if used long-term; taper under medical supervision to avoid withdrawal.
"Dantrolene, a direct-acting skeletal muscle relaxant, may inhibit the hepatic cytochrome P450 (CYP) enzymes responsible for metabolizing the antihistamine clemastine. This metabolic inhibition can lead to elevated plasma concentrations of clemastine, prolonging its sedative and anticholinergic effects. Clinically, patients may experience increased sedation, dizziness, and anticholinergic adverse effects such as dry mouth, blurred vision, and urinary retention."
"The concomitant use of Thiamylal, a barbiturate anesthetic that enhances GABA-A receptor activity, and Dantrolene, a direct-acting skeletal muscle relaxant that inhibits calcium release from the sarcoplasmic reticulum, can lead to additive central nervous system depression and muscle weakness. This interaction may result in prolonged sedation, respiratory depression, and decreased muscle tone, increasing the risk of aspiration and hypoventilation during anesthesia. Clinically, patients may exhibit excessive somnolence delayed recovery from anesthesia, and potential cardiovascular instability."
"Vecuronium, a non-depolarizing neuromuscular blocking agent, enhances the neuromuscular blocking effects of dantrolene, a direct-acting skeletal muscle relaxant used in malignant hyperthermia. This synergistic interaction leads to prolonged and intensified muscle paralysis, increasing the risk of postoperative respiratory depression and prolonged mechanical ventilation. Clinically, patients may exhibit delayed recovery of neuromuscular function and require extended monitoring in the intensive care setting."
"Lumacaftor is a strong inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes, including CYP2E1. Chlorzoxazone is primarily metabolized by CYP2E1 to its inactive metabolite. Concomitant use increases CYP2E1 activity, leading to accelerated chlorzoxazone clearance and reduced systemic exposure, potentially diminishing its therapeutic effect as a muscle relaxant."
"Chlorzoxazone, a centrally acting muscle relaxant, inhibits the metabolism of diltiazem, a calcium channel blocker, via competitive inhibition of CYP3A4. This leads to increased plasma concentrations of diltiazem, potentially causing enhanced negative chronotropic and vasodilatory effects, resulting in bradycardia, hypotension, or atrioventricular block. Patients may experience dizziness, syncope, or exacerbate heart failure symptoms."
"Butalbital, a barbiturate, induces hepatic cytochrome P450 enzymes (particularly CYP2E1), accelerating the metabolism of chlorzoxazone, a centrally acting muscle relaxant primarily metabolized by CYP2E1. This results in reduced plasma concentrations of chlorzoxazone, leading to diminished therapeutic efficacy and potential loss of symptom control. Clinically, patients may experience inadequate muscle relaxation, requiring dose adjustments or alternative therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DANTROLENE SODIUM vs CHLORZOXAZONE, answered by our medical review team.
DANTROLENE SODIUM is a Skeletal Muscle Relaxant that works by Dantrolene sodium dissociates the excitation-contraction coupling in skeletal muscle by inhibiting calcium release from the sarcoplasmic reticulum via ryanodine receptor blockade.. CHLORZOXAZONE is a Skeletal Muscle Relaxant that works by Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DANTROLENE SODIUM and CHLORZOXAZONE depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DANTROLENE SODIUM is: 25 mg orally once daily for 7 days; then 25 mg three times daily for 7 days; then 50 mg three times daily for 7 days; then 100 mg three times daily. Maximum daily dose: 400 mg. For malignant hyperthermia: 1 mg/kg intravenously, may repeat up to cumulative dose of 10 mg/kg.. The standard adult dose of CHLORZOXAZONE is: 250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DANTROLENE SODIUM and CHLORZOXAZONE. The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dantrolene. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DANTROLENE SODIUM is classified as Category A/B. Dantrolene sodium is not associated with major congenital malformations; however, data are limited. In animal studies, doses above human therapeutic range caused fetal toxicity (re. CHLORZOXAZONE is classified as Category C. Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if cl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.